Learn Before
Findings supporting heparin use in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Overall, heparin use did not improve outcomes. However, in severe COVID-19 cases with a sepsis-induced coagulopathy (SIC) score of 4 or higher and patients with D-dimer levels above 6 times normal levels, heparin treatment reduced 28-day mortality rates.
- results for heparin vs. no anticoagulants by SIC score
- results for heparin vs. no anticoagulants by D-dimer level
- results for univariate analysis for other clotting factors
- patient characteristics
- SIC score
- methods
- discussion
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Findings supporting heparin use in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Prophylactic and Therapeutic Serum Concentrations of Unfractionated Heparin (UFH)
Prophylactic and Therapeutic Serum Concentrations of Low Molecular Weight Heparins (LMWH)
SARS-CoV-2 S Protein May Have Multiple Heparin Binding Sites
Comparison of Unfractionated and Low-Molecular-Weight Heparins in Anti-ACE2-Treated RT4 Cells
Learn After
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group